Sign In
Buy EXEL
$56.70
+0.700 (+1.25%)
At Close: Aug 05, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
11:04am, Sunday, 17'th Aug 2025
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:00am, Saturday, 16'th Aug 2025
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
10:16am, Thursday, 14'th Aug 2025
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
11:04am, Wednesday, 13'th Aug 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors a
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
09:55am, Wednesday, 13'th Aug 2025
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:00am, Monday, 11'th Aug 2025
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
11:40am, Saturday, 09'th Aug 2025
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
06:40pm, Wednesday, 06'th Aug 2025
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:30am, Wednesday, 06'th Aug 2025
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
10:11am, Tuesday, 05'th Aug 2025
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock
10:17am, Monday, 04'th Aug 2025
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
06:45pm, Thursday, 31'st Jul 2025
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
12:27pm, Thursday, 31'st Jul 2025
EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib alt
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Wednesday, 30'th Jul 2025
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
10:36pm, Tuesday, 29'th Jul 2025
Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixi
